Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory B-cell Non-hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchActive Not RecruitingNCT04161248
What this trial is testing

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Canadian Cancer Trials Group 40
Testing effectiveness (Phase 2)Ended earlyNCT02592876
What this trial is testing

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Who this might be right for
Lymphoma, B-cellLymphoma, Large B-Cell, DiffuseLymphoma, Follicular, Grade 3b+1 more
Seagen Inc. 81
Early research (Phase 1)Study completedNCT03939026
What this trial is testing

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

Who this might be right for
Relapsed/Refractory Large B Cell LymphomaRelapsed/Refractory Follicular Lymphoma
Allogene Therapeutics 50
Very early researchLooking for participantsNCT04227015
What this trial is testing

CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Who this might be right for
Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma
He Huang 72
Very early researchUnknownNCT06045585
What this trial is testing

JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Lymphoma
Guangdong Second Provincial General Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT06542250
What this trial is testing

Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Who this might be right for
B-cell Malignancies
AstraZeneca 174
Testing effectiveness (Phase 2)Study completedNCT00156013
What this trial is testing

Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Lymphoma, B-CellLymphoma, Non-Hodgkin
Oncology Specialists, S.C. 33
Testing effectiveness (Phase 2)Study completedNCT01562990
What this trial is testing

Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

Who this might be right for
Diffuse Large B-Cell Lymphoma
The Lymphoma Academic Research Organisation 11
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07774234
What this trial is testing

Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma

Who this might be right for
Large B-Cell Lymphoma (LBCL)High-grade B-cell Lymphoma
The First Affiliated Hospital of Soochow University 39
Testing effectiveness (Phase 2)Ended earlyNCT02594163
What this trial is testing

Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma RefractoryFollicular B-cell Non-Hodgkin's Lymphoma
Seagen Inc. 25
Early research (Phase 1)Study completedNCT01460134
What this trial is testing

CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Who this might be right for
CD27 Expressing B-cell Malignancies for Example Hodgkin's LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+7 more
Celldex Therapeutics 90
Testing effectiveness (Phase 2)UnknownNCT03156101
What this trial is testing

A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects

Who this might be right for
Relapsed B-cell Acute Lymphoblastic LeukemiaRefractory B-cell Acute Lymphoblastic LeukemiaRelapsed／Refractory B-cell Lymphoma
Shenzhen BinDeBio Ltd. 24
Early research (Phase 1)Study completedNCT00012207
What this trial is testing

Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Fred Hutchinson Cancer Center 12
Early research (Phase 1)Looking for participantsNCT05054257
What this trial is testing

CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaNon-Hodgkin's Lymphoma RefractoryNon-Hodgkin's Lymphoma, Relapsed
Institute of Hematology and Blood Transfusion, Czech Republic 10
Large-scale testing (Phase 3)Study completedNCT04182204
What this trial is testing

Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche 270
Testing effectiveness (Phase 2)Study completedNCT03456726
What this trial is testing

Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Eisai Co., Ltd. 20
Testing effectiveness (Phase 2)Looking for participantsNCT07042438
What this trial is testing

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma+3 more
City of Hope Medical Center
Testing effectiveness (Phase 2)Study completedNCT00295932
What this trial is testing

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Memorial Sloan Kettering Cancer Center 79
Early research (Phase 1)Ended earlyNCT04045028
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Multiple MyelomaNon-Hodgkin LymphomaB-Cell Lymphoma
Genentech, Inc. 41
Testing effectiveness (Phase 2)Study completedNCT02077166
What this trial is testing

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Relapsed Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
Pharmacyclics LLC. 138
Next Page
56